Australia markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.19-0.25 (-2.96%)
At close: 04:00PM EST
8.50 +0.31 (+3.79%)
Pre-market: 05:40AM EST

Nuvectis Pharma, Inc.

1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
United States
201 614 3150

Full-time employees11

Key executives

NameTitlePayExercisedYear born
Mr. Ron Bentsur M.B.A.Co-Founder, Chairman, CEO & President851.61kN/A1966
Dr. Enrique Poradosu Ph.D.Co-Founder, Executive VP, Chief Scientific & Business Officer549.07kN/A1967
Mr. Shay ShemeshCo-Founder, Executive VP, Chief Development & Operations Officer529.27kN/A1984
Mr. Michael Carson CPAVice President of FinanceN/AN/A1976
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Corporate governance

Nuvectis Pharma, Inc.’s ISS governance QualityScore as of 1 December 2023 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.